Exploration of flavonoids from Physcomitrella patens for determining its antimicrobial potential

A. Gupta¹ , S. Shah² , G.G. Saiyed³ , S.A. Pathan⁴ , H.F. Dudha⁵ , S.S. Das⁶ , S. Palekar⁷

Section:Research Paper, Product Type: Isroset-Journal
Vol.5 , Issue.4 , pp.76-81, Aug-2018

CrossRef-DOI:   https://doi.org/10.26438/ijsrbs/v5i4.7681

Online published on Aug 31, 2018

Copyright © A. Gupta, S. Shah, G.G. Saiyed, S.A. Pathan, H.F. Dudha, S.S. Das, S. Palekar . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

View this paper at   Google Scholar | DPI Digital Library

XML View     PDF Download

How to Cite this Paper

1105 Views    375 Downloads    117 Downloads

Abstract :
Bryophytes (e.g. mosses) is one of the largest taxonomical group and also considered them as an important component of ecosystem. Traditionally, these mosses are widely used in the form of extract (primary/secondary metabolites) and showed immunopharmacological properties (e.g. for curing tuberculosis, pneumonia, neurasthenia and other illnesses) as well. The major primary components of mosses i.e. carbohydrates and secondary metabolites (e.g. flavonoids, terpenoids etc.) showing some immunopharmacological activity. Till date, composition and characterization of only few mosses has been studied in detail with respect to immunopharmacological applications. In the present study, extract the flavonoid from moss species which is identified through qualitative (lead acetate and thin layer chromatography, TLC) and determined its antimicrobial activity against various bacterial strains. The results showed the presence of flavonoids at higher concentration showing inhibitory action against various bacterial strains as compared to control. These studies which clearly indicates its antimicrobial activity. In short, these mosses are considered to be one of the most potent and attractive candidate for human health diseases.

Key-Words / Index Term :
Bryophytes, primary, secondary, metabolites, immunopharmacological

References :
[1]. M. Konrat, A.J. Shaw, K.S. Renzaglia, “A special issue of Phytotaxa dedicated to Bryophytes: The closest living relatives of early land plants” Phytotaxa, Vol, 9, pp. 5-10, 2010.
[2]. P. Kenrick, P.R. Crane, “The origin and early evolution of plants on land, Nature, Vol 389, S. No. 6646, pp. 33–39, 1997.
[3]. E.L. Decker, R. Reski, “Moss bioreactors producing improved biopharmaceuticals,” Current Opinion in Biotechnology, Vol. 18, S. No. 5, pp. 393–398, 2007.
[4]. R. Mishra, V.K. Pandey, R. Chandra, “Potential of bryophytes as therapeutics,” International journal of pharmaceutical sciences and research, Vol. 3, pp. 3584-3593, 2014.
[5]. D.J. Cove, C.D. Knight, T. Lamparter, “Mosses as model systems,” Trends Plant Science, Vol. 2, pp. 99-105, 1997.
[6]. W.O. Abel, W. Knebel, H.U. Koop, J.R. Marienfeld, H. Quader, R. Reski, E. Schnepf, B. Spörlein, “A cytokinin-sensitive mutant of the moss, Physcomitrella patens, defective in chloroplast division,” Protoplasma, Vol. 152, pp. 1-13, 1989.
[7]. Y. Hiwatashi, T. Nishiyama, F. Tomomichi, M. Hasebe, “Establishment of gene-trap and enhancer-trap in the moss Physcomitrella patens,” Plant Journal, Vol. 28, pp. 105-116, 2001.
[8]. N.T. Krogan, N.W. Ashton, “Ancestry of plant MADS box genes revealed by bryophyte (Physcomitrella patens) homologues,” New Phytol, Vol. 147, pp. 505-517, 2000.
[9]. R. Reski, J. Parsons, E.L. Decker, “Moss-made pharmaceuticals: from bench to bedside,” Plant Biotechnology Journal, Vol. 13, pp. 1191–1198, 2015.
[10]. D. Lang, A.D. Zimmer, S.A. Rensing, R. Reski, “Exploring plant biodiversity: the Physcomitrella genome and beyond,” Trends in Plant Science, Vol. 13, pp. 542–549, 2008.
[11]. M. Hubers, H. Kerp. Oldest known mosses discovered in Mississippian (late Visean) strata of Germany. Geology, Vol. 40, S.No. 8, pp. 755–758, 2012.
[12]. R. Reski, W. Frank, “Moss (Physcomitrella patens) functional genomics – Gene discovery and tool development with implications for crop plants and human health,” Briefings in Functional Genomics and Proteomics, Vol. 4, pp. 48-57, 2005.
[13]. D.T. Hanson, S.K. Rice, “Photosynthesis in Bryophytes and Early Land Plants,” Springer, Vol. 37; S.No. 8, 2014.
[14]. C.F. Xie, H.X. Lou, “Secondary metabolites in bryophytes: an ecological aspect,” Chem Biodivers, Vol. 6, S. No. 3, pp. 303-312, 2009.
[15]. X. Wang, J. Cao, X. Dai, J. Xiao, Y. Wu, Q. Wang, “Total flavonoid concentrations of bryophytes from Tianmu Mountain, Zhejiang Province (China): Phylogeny and ecological factors,” PLOS ONE, Vol. 12, S. No. 6, pp. e0179837, 2017.
[16]. A. Gupta, S.R. Chaphalkar, “Immunopharmacological activity of flavonoids isolated from Mesua ferrea, Ficus benghalensis and Jasminum auriculatum,” Current Life Sciences, Vol. 2, S.No.2, pp. 49-54, 2016.
[17]. M. Ali, V. Agrawal, “Thin-layer chromatography of aromatic amines,” Separation Science and Technology, Vol. 37, pp. 363 – 377, 2002.
[18]. S. Singhal, N. Singhal, S. Agarwal, “Pharmaceutical Analysis II, Thin layer chromatography,” Pragati prakashan First edition, pp 98-111, 2009.
[19]. M. Khurram et al, “Evaluation of anticandidal potential of Quercus baloot Griff. Using contact bioautography technique,” Afr J Pharm Pharmacol, Vol. 5, S.No. 12, pp. 1538–1542, 2012.
[20]. S.G. Ciancio, “Antiseptics and antibiotics as chemotherapeutic agents for periodontitis management,” Compend Contin Educ Dent, Vol. 21, S. No. 1, pp. 59-62, 2000.
[21]. A.E. Allsop, “New antibiotic discovery, novel screens, novel targets and impact of microbial genomics,” Curr Opin Microbiol, Vol. 1, pp. 530-534, 1998.
[22]. M.R. Barbachyn, E.M. John, “Recent advances in the discovery of hybrid antibacterial agents,” Annu Rep Med Chem, Vol. 43, pp. 281-290, 2008.
[23]. J.J. Barker, “Antibacterial drug discovery and structure-based design,” Drug Discov Today, Vol. 11, pp. 391 – 404, 2006.
[24]. M. Itouga, M. Hayatsu, M. Sato, Y. Tsuboi, Y. Kato, K. Toyooka et al, “Protonema of the moss Funaria hygrometrica can function as a lead (Pb) adsorbent,” PLoS ONE, Vol. 12, S. No. 12, pp. e0189726, 2017.
[25]. S. Friederich, U.H. Maier, B. Deus-Neumann, “Biosynthesis of cyclic bis (bibenzyls) in Marchantia polymorpha,” Phytochemistry, Vol. 50, pp. 589-598, 1999.
[26]. M. Singh, R. Govindarajan, V. Nath, A.K.S. Rawat, S. Mehrotra, “Antimicrobial, wound healing and antioxidant activity of Plagiochasma appendiculatum, Journal of Ethnopharmacology, Vol. 107, S. No. 1, pp. 67-72, 2006.
[27]. K. Szczepaniak, A. Astel, V. Simeonov S. Tsakovski, M. Biziuk, P. Bode, A. Przyjazny, “Comparison of dry and living Sphagnum palustre moss samples in determining their biocumulative capability as biomonitoring tools,” J Environ Sci Health A Tox Hazard Subst Environ Eng, Vol. 42, S.No. 8, pp. 1101-1115, 2007
[28]. D.G. Schaefer, J.P. Zryd, “Efficient gene targeting in the moss Physcomitrella patens,” Plant Journal, Vol. 11, S. No. 6, pp. 1195–1206, 1997.
[29]. D.G. Schaefer, “A new moss genetics: targeted mutagenesis in Physcomitrella patens, “Annual Review of Plant Biology, 53, 477–501, 2002.
[30]. E.L. Decker, R. Reski, “Moss bioreactors producing improved biopharmaceuticals,” Current Opinion in Biotechnology, Vol. 18, S. No. 5, pp. 393–398, 2007.
[31]. Gitzinger et al, “Functional cross-kingdom conservation of mammalian and moss (Physcomitrella patens) transcription, translation and secretion machineries,”. Plant Biotechnology Journal, Vol. 7, S. No. 1, pp. 73, 2009.
[32]. Maddi R, Kandula LV, Vallepu B, Navuluri H, Kollu H, “Preliminary Phytochemical Analysis and Invitro Anti–viral Activity of Ethanolic extract of Whole plant of Tinospora cordifolia (Thunb.) Miers against Hepatitis-A Virus,” International Journal of Scientific research in biological Sciences, Vol.5 , Issue 3, pp.51-55, 2018